Ram Aiyar
Chief Executive Officer at Korro Bio, Inc.
Net worth: 269 999 $ as of 30/04/2024
Profile
Dr. Ram Aiyar is a President, Chief Executive Officer & Director at Korro Bio, Inc., a President, Chief Executive Officer & Director at Korro Bio, Inc. (United States) and an Advisor at Atlas Venture Advisors, Inc. He is on the Board of Directors at Korro Bio, Inc., Korro Bio, Inc. (United States), Protean Bio, Inc. and Triveni Bio, Inc. Dr. Aiyar was previously employed as a CFO, Executive VP & Head-Business Development by Corvidia Therapeutics, Inc., a Chief Commercial Officer by FlowMetric LLC, and an Associate by Sofinnova Partners SAS.
He also served on the board at Avidea Technologies, Inc. He received his undergraduate degree from the University of Mumbai, a graduate degree from Drexel University, an MBA from INSEAD and a doctorate degree from Drexel University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.06% | 17/04/2024 | 4,613 ( 0.06% ) | 269 999 $ | 30/04/2024 |
Ram Aiyar active positions
| Companies | Position | Start |
|---|---|---|
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Chief Executive Officer | 10/11/2020 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
Former positions of Ram Aiyar
| Companies | Position | End |
|---|---|---|
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Founder | 01/11/2020 |
FlowMetric LLC
 FlowMetric LLC Medical/Nursing ServicesHealth Services FlowMetric, Inc. provides flow cytometry and cell sorting services. It serves partners in multiple fields including biotechnology, small and large cap pharmaceuticals, hospitals and academic institutions. The firm provides flow cytometry, pre-clinical, pre-clinical toxicology and safety, clinical, cell sorting, monoclonal antibody production, and agri-food services. The company was founded by Renold Capocasale in 2010 and is headquartered in Doylestown, PA. | Corporate Officer/Principal | 01/05/2013 |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Private Equity Analyst | 01/10/2012 |
Avidea Technologies, Inc.
 Avidea Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Vaccitech Plc, Avidea Technologies, Inc. is a biotechnology company based in Baltimore, MD. Avidea is advancing the next generation of safer and more effective T cell immunotherapies for treating cancer, infections, and autoimmune diseases. The company's precision immunotherapies are enabled by polymer-drug conjugate technologies, which are purpose-built to address the need for improved T cell and antibody-based immunotherapies. The company was founded by Geoffrey Lynn and Andrew Ishizuka, and Geoffrey Lynn has been the CEO since incorporation. Avidea was acquired by Vaccitech Plc on December 13, 2021 for $40 million. | Director/Board Member | - |
Training of Ram Aiyar
| Drexel University | Doctorate Degree |
| INSEAD | Masters Business Admin |
| University of Mumbai | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
FlowMetric LLC
FlowMetric LLC Medical/Nursing ServicesHealth Services FlowMetric, Inc. provides flow cytometry and cell sorting services. It serves partners in multiple fields including biotechnology, small and large cap pharmaceuticals, hospitals and academic institutions. The firm provides flow cytometry, pre-clinical, pre-clinical toxicology and safety, clinical, cell sorting, monoclonal antibody production, and agri-food services. The company was founded by Renold Capocasale in 2010 and is headquartered in Doylestown, PA. | Health Services |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Health Technology |
Avidea Technologies, Inc.
Avidea Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Vaccitech Plc, Avidea Technologies, Inc. is a biotechnology company based in Baltimore, MD. Avidea is advancing the next generation of safer and more effective T cell immunotherapies for treating cancer, infections, and autoimmune diseases. The company's precision immunotherapies are enabled by polymer-drug conjugate technologies, which are purpose-built to address the need for improved T cell and antibody-based immunotherapies. The company was founded by Geoffrey Lynn and Andrew Ishizuka, and Geoffrey Lynn has been the CEO since incorporation. Avidea was acquired by Vaccitech Plc on December 13, 2021 for $40 million. | Commercial Services |
- Stock Market
- Insiders
- Ram Aiyar
